RxDoctor Payments Data

Erlinda Grey, MD

General Practice · Panorama City, CANPI 1356568752

Payments from drug & device makers

$4,216in general payments, 2019–2025

Across 249 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$737
  • Lilly USA, LLC$480
  • Sanofi-aventis U.S. LLC$316
  • Novo Nordisk$310
  • Merck$306
  • Boehringer Ingelheim$286
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,15298%
  • Education$642%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,216 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$60,361
Medicare patients
222
Services billed
982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin150$186,191
JanuviaSitagliptin Phosphate64$84,076
VascepaIcosapent Ethyl170$75,369
EliquisApixaban74$72,221
KerendiaFinerenone44$53,678
TrulicityDulaglutide43$50,316
Icosapent Ethyl196$41,114
OzempicSemaglutide39$38,554
FarxigaDapagliflozin Propanediol34$38,053
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$35,632
RybelsusSemaglutide13$25,340
LinzessLinaclotide29$24,978
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog58$24,065
MounjaroTirzepatide21$23,968
TradjentaLinagliptin25$23,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$286$209,868175 claims
MerckJanuvia, Janumet, Dulera$306$109,27492 claims
Lilly USA, LLCTrulicity, Mounjaro$480$74,28464 claims
PfizerEliquis$37$72,22174 claims
Novo NordiskOzempic, Rybelsus$310$63,89352 claims
BayerKerendia$94$53,67844 claims
GSKTrelegy Ellipta, Breo Ellipta$205$50,16987 claims
AbbVieLinzess, Creon$737$48,46748 claims
AstraZenecaFarxiga$198$38,05334 claims
NovartisEntresto$38$12,45711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.

Other general practice in Panorama City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →